Development of cancer-specific autoantibody assay for early detection of gastric cancer
Title of the project: “Development of cancer-specific autoantibody assay for early detection of gastric cancer”
This project is supported by the European Regional Development Fund, project No. 2013/0052/2DP/22.214.171.124.0/13/APIA/VIAA/019
Collaboration partners: Latvian Biomedical Research and Study centre, GASTRO Ltd, AHL Ltd.
Funding: 374 746.02 EUR (BMC – 159 361,64 EUR, GASTRO Ltd – 106 715,39 EUR, AHL Ltd – 94 265,26 EUR)
Project duration: 20 months (1. January, 2014 – 31. August, 2015)
Project leader: Dr. Aija Linē
The main aim of the project is to develop a novel in vitro diagnostic tool – an autoantibody-based assay for the early detection of gastric cancer (GC). The specific aims of the project are the following:
To define a panel of antigens with GC-specific reactivity using a previously established cancer antigen database and clone collection, and to establish its diagnostic value in a retrospective study.
To establish its relevance for discriminating GC from other cancers of digestive system.
To develop a database of the retrospectively and prospectively collected clinical samples of GC patients and population-based cohort.
To validate the diagnostic performance of the autoantibody-based assay in a population-based cohort.
To evaluate the suitability of PYV virus-like particles as epitope carriers for the production of the autoantibody assay.